Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder.

INTRODUCTION:Major depression is a common, disabling mental health condition associated with the highest disease burden for any neuropsychiatric disorder worldwide according to the WHO. Due to the imperfect efficacy and tolerability profiles of existing treatments, investigational compounds in novel treatment classes are needed. Opioid-receptor antagonists are a potential new class of treatments currently under investigation. AREAS COVERED:Major depressive disorder is first overviewed. Existing treatments, both their mechanisms of action and their place within the antidepressant space, are discussed herein. Then the profile of Aticaprant and the wider context of kappa-opioid antagonism for depression is discussed in focus. EXPERT OPINION:Early evidence indicates Aticaprant may possess desirable pharmacodynamic and pharmacokinetic properties. A lack of convincing efficacy data at the time of writing precludes any definitive statement on its potential as an antidepressant.